Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-08-10
2011-12-27
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S254070, C514S397000, C514S253080
Reexamination Certificate
active
08084445
ABSTRACT:
Disclosed are novel formulations for the treatment of otic infections in an animal comprising a triazole anti-fungal compound, a quinolone antibiotic and a corticosteroid such as mometasone furoate monohydrate.
REFERENCES:
patent: 4235892 (1980-11-01), Nagabhushan
patent: 4311857 (1982-01-01), Nagabhushan
patent: 4443430 (1984-04-01), Mattei et al.
patent: 4582918 (1986-04-01), Nagabhushan et al.
patent: 4743700 (1988-05-01), Jommi et al.
patent: 4820695 (1989-04-01), Debono et al.
patent: 4876352 (1989-10-01), Schumacher et al.
patent: 4973750 (1990-11-01), Nagabhushan et al.
patent: 5104868 (1992-04-01), McGuirk
patent: 5105009 (1992-04-01), Jommi et al.
patent: 5198220 (1993-03-01), Damani
patent: 5227494 (1993-07-01), Schumacher et al.
patent: 5242910 (1993-09-01), Damanj
patent: 5352832 (1994-10-01), Wu et al.
patent: 5382673 (1995-01-01), Clark et al.
patent: 5491139 (1996-02-01), Demuth et al.
patent: 5496947 (1996-03-01), Yoon et al.
patent: 5498615 (1996-03-01), Kim et al.
patent: 5530116 (1996-06-01), Demuth et al.
patent: 5567844 (1996-10-01), Jommi et al.
patent: 5646163 (1997-07-01), Demuth et al.
patent: 5661151 (1997-08-01), Saksena et al.
patent: 5663361 (1997-09-01), Towson et al.
patent: 5672600 (1997-09-01), Demuth et al.
patent: 5770597 (1998-06-01), Kim et al.
patent: 5834472 (1998-11-01), Sangekar et al.
patent: 5840333 (1998-11-01), Gousset et al.
patent: 5846971 (1998-12-01), Sangekar et al.
patent: 2002/0037877 (2002-03-01), Singh
patent: 2003/0064939 (2003-04-01), Sklavounos et al.
patent: 2003/0153516 (2003-08-01), Ponikau et al.
patent: 2010/0087409 (2010-04-01), Freehauf et al.
patent: 10109928 (1998-04-01), None
patent: WO 96/16055 (1996-05-01), None
patent: WO 00/15234 (2000-03-01), None
patent: 0189495 (2001-11-01), None
patent: WO 03/026671 (2003-04-01), None
patent: WO 2005/077360 (2005-08-01), None
Kumar et al., “Treatment of Otitis Externa in Dogs Associated withMalassezia pachydermatis”, Indian Vet. J., Jul. 2002, pp. 727-729, vol. 79, No. 7, XP008044549.
International Search Report for International Application No. PCT/US2005/028379.
Full English Translation of JP 10-109928 US—20 Pages.
Ghubash et al, “Evaluation of Adrenal Function in Small-Breed Dogs Receiving Otic Glucocorticoids”, Vetinary Dermatology, No. 25, pp. 363-368 (2004).
Moriello et al, “Adrenocortical Suppression Associated with topical Otic Administration of Glucocorticoids in Dogs”, JAVMA, vol. 193, No. 3, pp. 329-331 (1988).
Prakash et al, “Topical Mometasone—A Review of its pharmacological Properties and Therapeutic Use in the Treatment of Dermatological Disorders”, Drugs, vol. 55, No. 1, pp. 145-163 (1998).
Reeder et al, “Comparative Adrenocortical Suppression in Dogs with Otitis Externa Following Topical Otic Administration of Four Different Glucocorticoid-Containing Medications”, Veterinary Therapeutics, vol. 9, No. 2, pp. 111-121 (2008).
Schafer et al, “Novel Fluorine-Containing Analogs of Chloramphenicol and Thiamphenicol: Antibacterial and Biological Properties”, Current Chemotherapy and Infectious Disease Proceedings of the 11uthICC and the 19thICAAC American Society of Microbiology, pp. 444-446 (1980).
Zenoble et al, “Adrenocortical Suppression by Topically Applied Corticosteroids in Healthy Dogs”, JAVMA, vol. 191, No. 6 (1987).
Huq Abu S
Simmons Robert D
Weingarten Allan J
Blackstone William M.
Javanmard Sahar
Mathey Kiera A.
Padmanabhan Sreeni
Schering-Plough Animal Health Corporation
LandOfFree
Pharmaceutical formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4261040